These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 21673038)

  • 21. Risk factors for ocular chlamydia after three mass azithromycin distributions.
    Ayele B; Gebre T; Moncada J; House JI; Stoller NE; Zhou Z; Porco TC; Gaynor BD; Emerson PM; Schachter J; Keenan JD
    PLoS Negl Trop Dis; 2011 Dec; 5(12):e1441. PubMed ID: 22180804
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Geospatial distribution and clustering of Chlamydia trachomatis in communities undergoing mass azithromycin treatment.
    Yohannan J; He B; Wang J; Greene G; Schein Y; Mkocha H; Munoz B; Quinn TC; Gaydos C; West SK
    Invest Ophthalmol Vis Sci; 2014 Jun; 55(7):4144-50. PubMed ID: 24906862
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Evaluation of a Single Dose of Azithromycin for Trachoma in Low-Prevalence Communities.
    Wilson N; Goodhew B; Mkocha H; Joseph K; Bandea C; Black C; Igietseme J; Munoz B; West SK; Lammie P; Kasubi M; Martin DL
    Ophthalmic Epidemiol; 2019 Feb; 26(1):1-6. PubMed ID: 30543311
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Re-emergence of Chlamydia trachomatis infection after mass antibiotic treatment of a trachoma-endemic Gambian community: a longitudinal study.
    Burton MJ; Holland MJ; Makalo P; Aryee EA; Alexander ND; Sillah A; Faal H; West SK; Foster A; Johnson GJ; Mabey DC; Bailey RL
    Lancet; 2005 Apr 9-15; 365(9467):1321-8. PubMed ID: 15823382
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A randomized trial of two coverage targets for mass treatment with azithromycin for trachoma.
    West SK; Bailey R; Munoz B; Edwards T; Mkocha H; Gaydos C; Lietman T; Porco T; Mabey D; Quinn TC
    PLoS Negl Trop Dis; 2013; 7(8):e2415. PubMed ID: 24009792
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Community-level chlamydial serology for assessing trachoma elimination in trachoma-endemic Niger.
    Kim JS; Oldenburg CE; Cooley G; Amza A; Kadri B; Nassirou B; Cotter SY; Stoller NE; West SK; Bailey RL; Keenan JD; Gaynor BD; Porco TC; Lietman TM; Martin DL
    PLoS Negl Trop Dis; 2019 Jan; 13(1):e0007127. PubMed ID: 30689671
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Two-day dosing versus one-day dosing of azithromycin in children with severe trachoma in Tanzania.
    Campbell JP; Mkocha H; Munoz B; West SK
    Ophthalmic Epidemiol; 2012 Feb; 19(1):38-42. PubMed ID: 22273357
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Trachoma and ocular Chlamydia trachomatis rates in children in trachoma-endemic communities enrolled for at least three years in the Tanzania National Trachoma Control Programme.
    Mkocha H; Munoz B; West S
    Tanzan J Health Res; 2009 Jul; 11(3):103-10. PubMed ID: 20734706
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Risk factors for active trachoma and Chlamydia trachomatis infection in rural Ethiopia after mass treatment with azithromycin.
    Edwards T; Harding-Esch EM; Hailu G; Andreason A; Mabey DC; Todd J; Cumberland P
    Trop Med Int Health; 2008 Apr; 13(4):556-65. PubMed ID: 18282237
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Do infants increase the risk of re-emergent infection in households after mass drug administration for trachoma?
    West SK; Stare D; Mkocha H; Munoz B; Gaydos C; Quinn TC
    Invest Ophthalmol Vis Sci; 2011 Jul; 52(8):6040-2. PubMed ID: 21680866
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The efficacy of oral azithromycin in clearing ocular chlamydia: mathematical modeling from a community-randomized trachoma trial.
    Liu F; Porco TC; Mkocha HA; Muñoz B; Ray KJ; Bailey RL; Lietman TM; West SK
    Epidemics; 2014 Mar; 6():10-7. PubMed ID: 24593917
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Ocular immune responses, Chlamydia trachomatis infection and clinical signs of trachoma before and after azithromycin mass drug administration in a treatment naïve trachoma-endemic Tanzanian community.
    Ramadhani AM; Derrick T; Macleod D; Massae P; Malisa A; Mbuya K; Mtuy T; Makupa W; Roberts CH; Bailey RL; Mabey DCW; Holland MJ; Burton MJ
    PLoS Negl Trop Dis; 2019 Jul; 13(7):e0007559. PubMed ID: 31306419
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Two doses of azithromycin to eliminate trachoma in a Tanzanian community.
    Solomon AW; Harding-Esch E; Alexander ND; Aguirre A; Holland MJ; Bailey RL; Foster A; Mabey DC; Massae PA; Courtright P; Shao JF
    N Engl J Med; 2008 Apr; 358(17):1870-1. PubMed ID: 18434662
    [No Abstract]   [Full Text] [Related]  

  • 34. Mass treatment and the effect on the load of Chlamydia trachomatis infection in a trachoma-hyperendemic community.
    West ES; Munoz B; Mkocha H; Holland MJ; Aguirre A; Solomon AW; Bailey R; Foster A; Mabey D; West SK
    Invest Ophthalmol Vis Sci; 2005 Jan; 46(1):83-7. PubMed ID: 15623758
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The conjunctival microbiome before and after azithromycin mass drug administration for trachoma control in a cohort of Tanzanian children.
    Pickering H; Ramadhani AM; Massae P; Mafuru E; Malisa A; Mbuya K; Makupa W; Mtuy T; Derrick T; Houghton J; Bailey RL; Mabey DCW; Burton MJ; Holland MJ
    Front Public Health; 2022; 10():1015714. PubMed ID: 36324475
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Ocular Chlamydia trachomatis infection: elimination with mass drug administration.
    Wolle MA; West SK
    Expert Rev Anti Infect Ther; 2019 Mar; 17(3):189-200. PubMed ID: 30698042
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Serology for trachoma surveillance after cessation of mass drug administration.
    Martin DL; Bid R; Sandi F; Goodhew EB; Massae PA; Lasway A; Philippin H; Makupa W; Molina S; Holland MJ; Mabey DC; Drakeley C; Lammie PJ; Solomon AW
    PLoS Negl Trop Dis; 2015 Feb; 9(2):e0003555. PubMed ID: 25714363
    [TBL] [Abstract][Full Text] [Related]  

  • 38. When can antibiotic treatments for trachoma be discontinued? Graduating communities in three African countries.
    Ray KJ; Lietman TM; Porco TC; Keenan JD; Bailey RL; Solomon AW; Burton MJ; Harding-Esch E; Holland MJ; Mabey D
    PLoS Negl Trop Dis; 2009 Jun; 3(6):e458. PubMed ID: 19529761
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Profound and sustained reduction in Chlamydia trachomatis in The Gambia: a five-year longitudinal study of trachoma endemic communities.
    Burton MJ; Holland MJ; Makalo P; Aryee EA; Sillah A; Cohuet S; Natividad A; Alexander ND; Mabey DC; Bailey RL
    PLoS Negl Trop Dis; 2010 Oct; 4(10):. PubMed ID: 20957147
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Stopping azithromycin mass drug administration for trachoma: A systematic review.
    Mahmud H; Landskroner E; Amza A; Aragie S; Godwin WW; de Hostos Barth A; O'Brien KS; Lietman TM; Oldenburg CE
    PLoS Negl Trop Dis; 2021 Jul; 15(7):e0009491. PubMed ID: 34237074
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.